Imbed Biosciences announced today the results of a first prospective clinical evaluation of its next-generation wound dressing, Microlyte Matrix, in complex chronic wounds.

“This was a very professionally run prospective clinical study,” Imbed Biosciences CEO Ankit Agarwal said in a statement. “The outcomes of this clinical study reassure the choice of these clinicians in adopting Microlyte Matrix as their preferred primary antimicrobial dressing for mounds.”

According to a release, the study was conducted at Wound Healing and Hyperbaric Center at Mission Hospital in Asheville, N.C. Microlyte Matrix was applied to wounds once every three days and covered with a secondary dressing. After 12 weeks, 91 percent of wounds either healed completely improved significantly, with an average wound area reduction of 73 percent.

The results were published in the November issue of WOUNDS, a peer-reviewed journal in wound care and research.